{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-032774","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.682037+00:00","generated_at":"2026-06-18T01:50:04.685616+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Protagonist reports Q4 net loss $0.69/shr, cash $237M; positive Ph2b JNJ-2113 and rusfertide REVIVE data","bullets":["Net loss per share Q4 2022: $0.69 ($34.2M) vs $0.77 ($36.9M) in Q4 2021; full year 2022 net loss $127.4M.","Cash, cash equivalents and marketable securities $237.4M at Dec 31, 2022; expected to fund operations through end of 2024.","Phase 2b FRONTIER 1 study of JNJ-2113 in psoriasis met primary endpoint: statistically significant PASI-75 at Week 16 across all doses, well tolerated.","Phase 2 REVIVE study of rusfertide in polycythemia vera met primary endpoint: proportion of responders on rusfertide vs placebo p=0.0003; 92.3% phlebotomy-free.","License revenue from Janssen collaboration declined to zero in Q4 2022 as performance obligations completed June 2022; total milestones and royalties potential $855M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-032774","json":"https://secwatch.observer/filing/0001104659-23-032774.json","markdown":"https://secwatch.observer/filing/0001104659-23-032774.md","text":"https://secwatch.observer/filing/0001104659-23-032774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/0001104659-23-032774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/tm239503d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:50:04.685616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23c88649e06aab3cb51bf5936a10110974f55888","claim":"Protagonist Therapeutics, Inc reported the fourth quarter ended December 31, 2022 results: revenue zero.","evidence_excerpt":"License and Collaboration Revenue : License and collaboration revenue for the fourth quarter and full year 2022 were zero and $26.6 million, respectively, as compared to $8.6 million and $27.4 million for the same periods of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/0001104659-23-032774-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"zero"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"888d594de9b8660ef61bf183b6d92b9133e5b6b7","claim":"Protagonist Therapeutics, Inc reported the full year ended December 31, 2022 results: revenue $26.6 million.","evidence_excerpt":"License and Collaboration Revenue : License and collaboration revenue for the fourth quarter and full year 2022 were zero and $26.6 million, respectively, as compared to $8.6 million and $27.4 million for the same periods of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/0001104659-23-032774-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$26.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}